Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in HEMO?
HemoGenyx Pharmaceuticals: THE INVESTMENT CASE
INVESTMENT OVERVIEW

HemoGenyx optimistic on CDX antibodies prospects

HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX antibodies during the first half
HemoGenyx optimistic on CDX antibodies prospects
INVESTMENT OVERVIEW: HEMO The Big Picture
HemoGenyx is confident that its humanised mice will be of interest to large biopharmaceutical firms

HemoGenyx Pharmaceuticals PLC (LON:HEMO) said it was optimistic about the prospects for its CDX antibodies, which are under development, as it posted wider first-half losses.

The biopharmaceuticals group said that during the period, it had filed a patent for a new type of humanised mouse with a "chimeric mouse-human blood system" and had signed a development agreement, as well as receiving first data results, in relation to its CDX antibodies.

"Overall the board is very pleased with the progress being made, in particular the unlocking of opportunities for CDX antibodies, as well as the potential value that can be created through the company's new type of humanised mice," executive chairman Marc Feldmann said in a statement.

"Hemogenyx is confident that these humanised mice will be of interest to large biopharmaceutical companies and has the potential to form the basis of significant future collaborations and the company hopes to update shareholders on progress in this area," he added.

The group posted a pretax loss of £0.65mln in the six months to the end of June, up from a loss of £0.14mln a year ago, hit by administrative costs, which more than trebled to £0.7mln. The company’s therapies are still under development meaning the company is yet to produce any revenue.

Blood cancers hard to treat

Blood cancers are some of the most difficult to treat forms of the killer disease.

They take three major forms: Leukaemia, Lymphoma and Myeloma, all of which involve problems in a person’s bone marrow, the source of the cells in our blood - red, white or platelets.

The current standard of care treatment involves chemotherapy and radiotherapy and ultimately, in recurring cases, a bone marrow transplant.

Two major problems

All current treatments are dangerous, highly toxic and debilitating, with serious side effects.

Indeed, so traumatic is the transplant option that many patients are rejected on the grounds that they will not survive the conditioning process.

After that comes the problem of finding a donor.

Hemogenyx has developed products that deal with both problems and offer the possibility of transforming the current treatments for blood cancers, says Sandler.

Partially based around work undertaken by founder and chief executive Vladislav Sandler at Cornell University, which is now a shareholder in Hemogenyx, they target a market estimated to be currently worth between US$8bn - US$9bn.

CDX antibodies, the first product, tackle the pre-transplant, conditioning stage.

A more benign alternative to the current standard of care, it will eliminate chemotherapy and radiotherapy by targeting and killing only “unwanted” cells (not everything) and allowing many more people who would otherwise be deemed unfit enough to receive a transplant.

Pre-clinical trials on humanised animals have already proved it as a concept, says Sandler.

A Phase I clinical trial though only a safety study will give a good indication of its potential.

Trial patients will only have a few months to live and they will either survive after treatment or not.

Stem cell treatment

Hemogenyx’s second product effectively replaces a patient’s cancer-infected blood with a new, clean, supply generated from their own stem cells.

As these blood stem cells have not been through the body’s circulatory system, they have not accumulated the mutations or chromosome rearrangements that cause the cancer.

“In effect, they reset blood generation back to zero” says Sandler.

These blood stem-like cells can also be found in everybody’s liver, he adds.

 

 

 

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

1538141963_shutterstock_795297598.jpg
September 28 2018
HemoGenyx said it was pleased with the opportunities that had been unlocked for its CDX antibodies during the first half
cannabis plant
February 01 2018
Today, the group closed the US$18mln acquisition of Citiva Medical and Citiva USA

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use